Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016; 22(38): 8447-8458 [PMID: 27784957 DOI: 10.3748/wjg.v22.i38.8447]
Corresponding Author of This Article
Dr. Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com
Research Domain of This Article
Hematology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 14, 2016; 22(38): 8447-8458 Published online Oct 14, 2016. doi: 10.3748/wjg.v22.i38.8447
Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma
Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco
Michele Merli, Division of Hematology, University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria, 36100 Varese, Italy
Giuseppe Carli, Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, 36100 Vicenza, Italy
Luca Arcaini, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
Author contributions: Merli M and Visco C made the research; all authors revised the manuscript and gave final inputs before submission.
Conflict-of-interest statement: Authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com
Telephone: +39-444-753626 Fax: +39-444-753626
Received: June 1, 2016 Peer-review started: June 2, 2016 First decision: July12, 2016 Revised: August 2, 2016 Accepted: August 23, 2016 Article in press: August 23, 2016 Published online: October 14, 2016 Processing time: 132 Days and 20.8 Hours
Core Tip
Core tip: In the last decade many clinical studies demonstrated that front line antiviral therapy (AT) with interferon (IFN) and ribavirin, is able to induce a 70%-75% response rate in patients with hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphoma who do not need immediate conventional treatment. Hematological response was durable, and invariably related to the viral eradication. International guidelines indicate that AT should be the treatment of choice in such patients. Very preliminary data about the use of the new direct-acting antiviral agents (DAAs) suggest a similar activity in inducing lymphoma response. We discuss available literature about IFN-based AT and preliminary experiences with DAAs in the treatment of HCV-associated indolent lymphomas.
